Viagra Patent Remains In Limbo In China

Law360, New York (April 14, 2004, 12:00 AM EDT) -- More than two years after China granted patent exclusivity for Pfizer’s Viagra anti-impotence drug, an onslaught of patent challenges has left the drug’s status in limbo, officials at China’s State Intellectual Property Office (SIPO) have conceded.

SIPO approved Pfizer's patent application for its anti-impotency drug Viagra in late 2001.

But shortly after the patent was approved, twelve of the country's pharmaceutical companies launched a patent challenge, and were later joined by three more.

SIPO has established a special committee to examine the case.

Wang Jingchuan, commissioner...
To view the full article, register now.